Published in J Clin Pathol on September 03, 2012
Tissue-resident Sca1+ PDGFRα+ mesenchymal progenitors are the cellular source of fibrofatty infiltration in arrhythmogenic cardiomyopathy. F1000Res (2013) 0.78
Arrhythmogenic right ventricular dysplasia/cardiomyopathy type 1: a light on molecular mechanisms. Genet Res Int (2013) 0.77
Genetic and toxicologic investigation of Sudden Cardiac Death in a patient with Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC) under cocaine and alcohol effects. Int J Legal Med (2014) 0.76
Transgenic mice overexpressing desmocollin-2 (DSC2) develop cardiomyopathy associated with myocardial inflammation and fibrotic remodeling. PLoS One (2017) 0.75
Prolactin mediates effects of chronic psychological stress on induction of fibrofatty cells in the heart. Am J Transl Res (2016) 0.75
Elevated Endomyocardial Biopsy Macrophage-Related Markers in Intractable Myocardial Diseases. Inflammation (2015) 0.75
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation (2005) 8.76
Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med (2010) 8.28
Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med (2008) 6.17
Prognostic importance of defibrillator shocks in patients with heart failure. N Engl J Med (2008) 5.13
An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm (2009) 4.99
Loss-of-function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST-segment elevation, short QT intervals, and sudden cardiac death. Circulation (2007) 4.37
Five-year risk of cardiac mortality in relation to initial severity and one-year changes in depression symptoms after myocardial infarction. Circulation (2002) 3.47
Cardiac resynchronization therapy in patients with heart failure and a QRS complex <120 milliseconds: the Evaluation of Resynchronization Therapy for Heart Failure (LESSER-EARTH) trial. Circulation (2013) 2.90
Arrhythmogenic right ventricular cardiomyopathy/dysplasia clinical presentation and diagnostic evaluation: results from the North American Multidisciplinary Study. Heart Rhythm (2009) 2.82
Quality of life and functional capacity in patients with atrial fibrillation and congestive heart failure. J Am Coll Cardiol (2012) 2.77
Obstructive sleep apnea in patients with typical atrial flutter: prevalence and impact on arrhythmia control outcome. Chest (2013) 2.69
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation (2013) 2.64
Brugada syndrome: report of the second consensus conference. Heart Rhythm (2005) 2.48
Natural history of Brugada syndrome: the prognostic value of programmed electrical stimulation of the heart. J Cardiovasc Electrophysiol (2003) 2.44
Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J Cardiovasc Electrophysiol (2005) 2.39
Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am Heart J (2005) 2.39
Atrial fibrillation promotion by endurance exercise: demonstration and mechanistic exploration in an animal model. J Am Coll Cardiol (2013) 2.38
Left ventricular versus simultaneous biventricular pacing in patients with heart failure and a QRS complex ≥120 milliseconds. Circulation (2011) 2.36
Cardiac resynchronization therapy: a meta-analysis of randomized controlled trials. CMAJ (2011) 2.28
De novo KCNQ1 mutation responsible for atrial fibrillation and short QT syndrome in utero. Cardiovasc Res (2005) 2.27
Current electrocardiographic criteria for diagnosis of Brugada pattern: a consensus report. J Electrocardiol (2012) 2.26
Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet (2002) 2.16
Effect of opening a new catheterization laboratory on 30-day and 2-year survival rates in myocardial infarction patients. Rev Esp Cardiol (2011) 2.14
Familial pseudo-Wolff-Parkinson-White syndrome. J Cardiovasc Electrophysiol (2006) 2.11
No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). J Am Coll Cardiol (2008) 2.03
Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing? Circulation (2005) 1.94
Efficacy and safety of cryoballoon ablation for atrial fibrillation: a systematic review of published studies. Heart Rhythm (2011) 1.93
Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol (2011) 1.92
Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation (2003) 1.92
Electrocardiographic changes predicting sudden death in propofol-related infusion syndrome. Heart Rhythm (2006) 1.91
Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation (2002) 1.91
Short QT syndrome: pharmacological treatment. J Am Coll Cardiol (2004) 1.87
Role of magnetic resonance imaging in arrhythmogenic right ventricular dysplasia: insights from the North American arrhythmogenic right ventricular dysplasia (ARVD/C) study. Am Heart J (2007) 1.86
Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. Eur Heart J (2007) 1.86
Cryptic 5' splice site activation in SCN5A associated with Brugada syndrome. J Mol Cell Cardiol (2004) 1.81
Induced Brugada-type electrocardiogram, a sign for imminent malignant arrhythmias. Circulation (2008) 1.81
Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol (2005) 1.74
The association of left atrial size and occurrence of atrial fibrillation: a prospective cohort study from the Canadian Registry of Atrial Fibrillation. Am Heart J (2004) 1.74
Electrophysiologic testing predicts events in Brugada syndrome patients. Heart Rhythm (2011) 1.70
Phenotypic characterization of a large European family with Brugada syndrome displaying a sudden unexpected death syndrome mutation in SCN5A:. J Cardiovasc Electrophysiol (2004) 1.69
Gender differences in clinical manifestations of Brugada syndrome. J Am Coll Cardiol (2008) 1.67
Dissociation between ionic remodeling and ability to sustain atrial fibrillation during recovery from experimental congestive heart failure. Circulation (2004) 1.64
Preparation for pacemaker or implantable cardiac defibrillator implants in patients with high risk of thrombo-embolic events: oral anticoagulation or bridging with intravenous heparin? A prospective randomized trial. Eur Heart J (2009) 1.63
Provocation of sudden heart rate oscillation with adenosine exposes abnormal QT responses in patients with long QT syndrome: a bedside test for diagnosing long QT syndrome. Eur Heart J (2005) 1.61
State of the art in forensic investigation of sudden cardiac death. Am J Forensic Med Pathol (2011) 1.61
Determinants of atrial fibrillation in an animal model of obesity and acute obstructive sleep apnea. Heart Rhythm (2012) 1.59
Pulmonary vein isolation using a second-generation cryoballoon catheter: a randomized comparison of ablation duration and method of deflation. J Cardiovasc Electrophysiol (2013) 1.57
Genetic and biophysical basis for bupivacaine-induced ST segment elevation and VT/VF. Anesthesia unmasked Brugada syndrome. Heart Rhythm (2006) 1.56
Epinephrine infusion in the evaluation of unexplained cardiac arrest and familial sudden death: from the cardiac arrest survivors with preserved Ejection Fraction Registry. Circ Arrhythm Electrophysiol (2012) 1.56
Brugada syndrome: 1992-2002: a historical perspective. J Am Coll Cardiol (2003) 1.54
Differences in atrial fibrillation properties under vagal nerve stimulation versus atrial tachycardia remodeling. Heart Rhythm (2009) 1.53
Quality of life improves with treatment in the Canadian Trial of Atrial Fibrillation. Am Heart J (2002) 1.53
Canadian Registry of ICD Implant Testing procedures (CREDIT): current practice, risks, and costs of intraoperative defibrillation testing. J Cardiovasc Electrophysiol (2009) 1.53
Elevated depression symptoms predict long-term cardiovascular mortality in patients with atrial fibrillation and heart failure. Circulation (2009) 1.52
Differences in 12-lead electrocardiogram between symptomatic and asymptomatic Brugada syndrome patients. J Cardiovasc Electrophysiol (2007) 1.52
Efficacy and safety of atrial fibrillation ablation with phased radiofrequency energy and multielectrode catheters. Heart Rhythm (2011) 1.51
Phenotypical manifestations of mutations in the genes encoding subunits of the cardiac sodium channel. Circ Res (2011) 1.51
Advances in paediatric interventional cardiology since 2000. Arch Cardiovasc Dis (2009) 1.50
The cloning, genomic organization and tissue expression profile of the human DLG5 gene. BMC Genomics (2002) 1.50
Targeting of rifamycin SV to the colon for treatment of travelers' diarrhea: a randomized, double-blind, placebo-controlled phase 3 study. J Travel Med (2014) 1.49
Pulmonary hemorrhage after cryoballoon ablation for pulmonary vein isolation in the treatment of atrial fibrillation. Chest (2014) 1.49
Fever and Brugada syndrome. Pacing Clin Electrophysiol (2002) 1.48
Mineralocorticoid receptor antagonists and cardiovascular mortality in patients with atrial fibrillation and left ventricular dysfunction: insights from the Atrial Fibrillation and Congestive Heart Failure Trial. Circ Heart Fail (2012) 1.48
Shocking truths about implantable cardioverter defibrillator monitoring zones. Pacing Clin Electrophysiol (2007) 1.48
Standardized approaches to the investigation of syncope: Canadian Cardiovascular Society position paper. Can J Cardiol (2011) 1.47
Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement. Europace (2013) 1.47
Persistent abdominal symptoms in US adults after short-term stay in Mexico. J Travel Med (2014) 1.47
Recommendations for the use of genetic testing in the clinical evaluation of inherited cardiac arrhythmias associated with sudden cardiac death: Canadian Cardiovascular Society/Canadian Heart Rhythm Society joint position paper. Can J Cardiol (2011) 1.47
Left ventricular systolic dysfunction by itself does not influence outcome of atrial fibrillation ablation. Europace (2010) 1.47
Anxiety sensitivity moderates prognostic importance of rhythm-control versus rate-control strategies in patients with atrial fibrillation and congestive heart failure: insights from the Atrial Fibrillation and Congestive Heart Failure Trial. Circ Heart Fail (2012) 1.47
Torsades de pointes following acute myocardial infarction: evidence for a deadly link with a common genetic variant. Heart Rhythm (2012) 1.46
Histopathology of cryoballoon ablation-induced phrenic nerve injury. J Cardiovasc Electrophysiol (2013) 1.45
KCNE2 modulation of Kv4.3 current and its potential role in fatal rhythm disorders. Heart Rhythm (2009) 1.43
Anodal right ventricular capture during left ventricular stimulation in CRT-implantable cardioverter defibrillators. Pacing Clin Electrophysiol (2005) 1.42
Group beating related T-wave alternans in a patient with atrio-ventricular nodal reentrant tachycardia. Europace (2011) 1.40
Enlargement of catheter ablation lesions in infant hearts with cryothermal versus radiofrequency energy: an animal study. Circ Arrhythm Electrophysiol (2011) 1.40
Rebuttal to EP testing does not predict cardiac events in patients with Brugada syndrome. Heart Rhythm (2011) 1.39
Focussing on hard science in forensic medicine: genetics of sudden cardiac death (SCD). Forensic Sci Int (2007) 1.39
Characterization of focal right atrial appendage tachycardia. Europace (2007) 1.39
Response to "Resolution of dyssynchronous left ventricular failure via cardiac resynchronization and subsequent radiofrequency ablation in an infant with preexcitation". Pediatr Cardiol (2010) 1.38
Prevention of Syncope Trial (POST): a randomized, placebo-controlled study of metoprolol in the prevention of vasovagal syncope. Circulation (2006) 1.32
Genetic fate mapping identifies second heart field progenitor cells as a source of adipocytes in arrhythmogenic right ventricular cardiomyopathy. Circ Res (2009) 1.28
Canadian Cardiovascular Society/Canadian Heart Rhythm Society position paper on implantable cardioverter defibrillator use in Canada. Can J Cardiol (2005) 1.25
Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management. Can J Cardiol (2011) 1.16